Current and Future Frontiers of Molecularly Defined Oligodendrogliomas.
1p19q codeletion
CODEL
EORTC
NCCN
POLCA
RTOG
diffuse glioma
oligodendroglioma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
05
2022
accepted:
13
06
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Oligodendrogliomas are a subtype of adult diffuse glioma characterized by their better responsiveness to systemic chemotherapy than other high-grade glial tumors. The World Health Organization (WHO) 2021 brain tumor classification highlighted defining molecular markers, including 1p19q codeletion and IDH mutations which have become key in diagnosing and treating oligodendrogliomas. The management for patients with oligodendrogliomas includes observation or surgical resection potentially followed by radiation and chemotherapy with PCV (Procarbazine, Lomustine, and Vincristine) or Temozolomide. However, most of the available research about oligodendrogliomas includes a mix of histologically and molecularly diagnosed tumors. Even data driving our current management guidelines are based on
Identifiants
pubmed: 35957904
doi: 10.3389/fonc.2022.934426
pmc: PMC9358027
doi:
Types de publication
Journal Article
Langues
eng
Pagination
934426Informations de copyright
Copyright © 2022 Rincon-Torroella, Rakovec, Materi, Raj, Vivas-Buitrago, Ferres, Reyes Serpa, Redmond, Holdhoff, Bettegowda and González Sánchez.
Déclaration de conflit d'intérêts
CB is a consultant for Depuy-Synthes, Bionaut Labs and Galectin Therapeutics and a co-founder of OrisDx. KR: Research support from Elekta AB, Accuray, Canon; Data Safety Monitoring Board for BioMimetix; Travel expenses from Brainlab, Elekta AB, Accuray, Icotec, RSS; Honorarium for speaking engagement NCCN, Accuray. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurosurgery. 2008 Oct;63(4):700-7; author reply 707-8
pubmed: 18981880
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51
pubmed: 17549014
CNS Oncol. 2015;4(5):317-23
pubmed: 26478133
Eur J Cancer. 2015 Oct;51(15):2231-2241
pubmed: 26421825
J Clin Oncol. 2014 Mar 10;32(8):783-90
pubmed: 24516018
Ann Oncol. 2014 Sep;25 Suppl 3:iii93-101
pubmed: 24782454
J Neurooncol. 2021 Jul;153(3):447-454
pubmed: 34125374
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237
J Neurooncol. 2022 Mar;157(1):197-205
pubmed: 35199246
Neuro Oncol. 2021 Mar 25;23(3):457-467
pubmed: 32678879
Curr Neurol Neurosci Rep. 2015;15(2):517
pubmed: 25467408
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Clin Cancer Res. 2014 Sep 15;20(18):4894-903
pubmed: 25078279
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
J Neurosurg. 2014 Feb;120(2):309-14
pubmed: 24313617
Neurooncol Adv. 2019 Dec 06;2(1):vdz048
pubmed: 33289010
J Clin Oncol. 2008 Mar 10;26(8):1338-45
pubmed: 18323558
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
J Korean Neurosurg Soc. 2013 Dec;54(6):489-95
pubmed: 24527191
Neuroradiology. 2017 Jun;59(6):555-562
pubmed: 28474187
J Neurooncol. 2022 May;157(3):511-521
pubmed: 35364762
Front Mol Neurosci. 2021 Oct 05;14:722396
pubmed: 34675774
Front Neurol. 2022 Jan 28;12:769345
pubmed: 35153976
Clin Transl Radiat Oncol. 2018 Dec 31;15:46-52
pubmed: 30656222
J Neurosurg. 2020 May 08;134(5):1357-1367
pubmed: 32384274
Science. 2011 Sep 9;333(6048):1453-5
pubmed: 21817013
J Neurooncol. 2021 Jun;153(2):283-291
pubmed: 33932195
J Neurooncol. 2019 Sep;144(3):591-601
pubmed: 31407129
Oncotarget. 2017 May 30;8(22):35523-35531
pubmed: 28388591
J Neurooncol. 2006 Sep;79(2):153-7
pubmed: 16855865
Neuro Oncol. 2011 Jun;13(6):649-59
pubmed: 21636710
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Am J Clin Oncol. 2019 Mar;42(3):258-264
pubmed: 30601146
J Neurooncol. 2015 Mar;122(1):111-9
pubmed: 25534576
J Neurosurg. 2019 Oct 25;:1-11
pubmed: 31653812
J Clin Oncol. 2006 Jun 20;24(18):2715-22
pubmed: 16782911
Oncotarget. 2012 Jul;3(7):709-22
pubmed: 22869205
J Neurooncol. 1997 Aug;34(1):85-101
pubmed: 9210055
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Clin Oncol. 2022 Feb 1;40(4):403-426
pubmed: 34898238